Catalent to offer GSK-developed compound optimisation platform

Catalent Pharma Solutions is offering Optiform, a GSK developed compound optimisation platform, to researchers for the first time.

GlaxoSmithKline (GSK) developed and refined the technology over the past 10 years, applying it to more than 500 compounds. Catalent is now offering it as a service to support clients compound optimisation efforts and help them shorten the time taken to bring a drug to market.

Optiform is a solid-state and highly-automated analysis platform for salt, crystal-form and co-crystal screening. It can be applied to compounds from early stage through to commercialised products to create faster and more material-efficient development workflows.

The platform and team behind it will now be integrated into Catalent’s 300-strong development and clinical services operations in Research Triangle Park (RTP), North Carolina, US.

David Igo, director, Optiform, said: "My team and I are very excited that other companies now have access to these industry-proven technologies and workflows​.

The pairing of leading-edge technology with a scientific team that has been embedded in hundreds of project teams to successfully address solid-state problems spanning lead-identification to commercial launch is unparalleled​."

SR One, GSK’s corporate venture fund, brokered the deal.

Service offering

Catalent will integrate Optiform into its existing portfolio of development and clinical services. This spans areas including analytical services, stability studies, biopharm product development and bioassay development.

We believe that the Optiform technology provides yet another means for Catalent to help our customers reduce development time and build a more robust product​”, said Kent Payne, vice president and general manager, development services at Catalent.

Related news

Show more

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars